Altre lingue Monte Rosa Therapeutics, Inc.

Azioni

GLUE

US61225M1027

Tempo differito Nasdaq Altri mercati azionari 21:59:21 21/06/2024			Variaz. 5gg	Var. 1 gen.
3,61 ^USD	+1,40%		-5,48%	-35,93%

14/06	Monte Rosa Therapeutics, Inc. presenta i dati preclinici a EULAR 2024, dimostrando il potenziale terapeutico di MRT-6160 per il trattamento dell'artrite reumatoide	CI
30/05	Monte Rosa Therapeutics, Inc. annuncia promozioni esecutive	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Monte Rosa Therapeutics : EULAR 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen Induced Arthritis Autoimmune Disease Model	14/06
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	14/06
Monte Rosa Therapeutics, Inc. Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	14/06
Monte Rosa Therapeutics Names Three Insiders to Leadership Team	30/05
Monte Rosa Therapeutics Announces Leadership Team Promotions	30/05
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference	30/05
Monte Rosa Therapeutics, Inc. Announces Executive Promotions	30/05
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Inhibits Disease Progression in a T cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression	21/05
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease	21/05
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	16/05
Monte Rosa Therapeutics Prices $100 Million Public Offering	16/05
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering	16/05
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	15/05
Monte Rosa Therapeutics : Corporate Presentation - May 2024	09/05
Monte Rosa Therapeutics: Q1 Earnings Snapshot	09/05
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	02/05
Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	02/05
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Monte Rosa Therapeutics, Inc.

Azioni

GLUE

US61225M1027

Altre lingue

Filtri